Patients from 2 years of age with active juvenile idiopathic arthritis (pJIA) who have responded inadequately to previous treatment with one or more biological disease-modifying anti-inflammatory drugs (bDMARDs). Appropriate comparator therapy: A change in bDMARD therapy (abatacept, or adalimumab, or etanercept, or golimumab, or tocilizumab) in combination with MTX; possibly as monotherapy, taking into account the case of MTX intolerance or unsuitability depending on previous therapy.

Patients from 2 years of age with active juvenile psroriatic arthritis (jPsA) who have responded inadequately to previous treatment with disease-modifying anti-inflammatory drugs DMARDs. Appropriate comparator therapy: Therapy as prescribed by a doctor.